Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Intratumoural Heterogeneity Underlies Distinct Therapy Responses and Treatment Resistance in Glioblastoma.

Akgül S, Patch AM, D'Souza RCJ, Mukhopadhyay P, Nones K, Kempe S, Kazakoff SH, Jeffree RL, Stringer BW, Pearson JV, Waddell N, Day BW.

Cancers (Basel). 2019 Feb 6;11(2). pii: E190. doi: 10.3390/cancers11020190.

2.

Genetically distinct glioma stem-like cell xenografts established from paired glioblastoma samples harvested before and after molecularly targeted therapy.

Tanaka S, Luk S, Kiyokawa J, Onozato ML, Iafrate AJ, Shah K, Martuza RL, Rabkin SD, Batchelor TT, Cahill DP, Chi AS, Wakimoto H.

Sci Rep. 2019 Jan 15;9(1):139. doi: 10.1038/s41598-018-37437-2.

3.

MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance.

Yip S, Miao J, Cahill DP, Iafrate AJ, Aldape K, Nutt CL, Louis DN.

Clin Cancer Res. 2009 Jul 15;15(14):4622-9. doi: 10.1158/1078-0432.CCR-08-3012. Epub 2009 Jul 7. Erratum in: Clin Cancer Res. 2013 Aug 15;19(16):4543-4.

4.

Glioblastomas are composed of genetically divergent clones with distinct tumourigenic potential and variable stem cell-associated phenotypes.

Stieber D, Golebiewska A, Evers L, Lenkiewicz E, Brons NH, Nicot N, Oudin A, Bougnaud S, Hertel F, Bjerkvig R, Vallar L, Barrett MT, Niclou SP.

Acta Neuropathol. 2014 Feb;127(2):203-19. doi: 10.1007/s00401-013-1196-4. Epub 2013 Oct 24.

5.

Discovery of Power-Law Growth in the Self-Renewal of Heterogeneous Glioma Stem Cell Populations.

Sugimori M, Hayakawa Y, Boman BM, Fields JZ, Awaji M, Kozano H, Tamura R, Yamamoto S, Ogata T, Yamada M, Endo S, Kurimoto M, Kuroda S.

PLoS One. 2015 Aug 18;10(8):e0135760. doi: 10.1371/journal.pone.0135760. eCollection 2015.

6.

Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives.

Saunders NA, Simpson F, Thompson EW, Hill MM, Endo-Munoz L, Leggatt G, Minchin RF, Guminski A.

EMBO Mol Med. 2012 Aug;4(8):675-84. doi: 10.1002/emmm.201101131. Epub 2012 Jun 25. Review.

7.

Ultra-deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas.

Gerlinger M, Quezada SA, Peggs KS, Furness AJ, Fisher R, Marafioti T, Shende VH, McGranahan N, Rowan AJ, Hazell S, Hamm D, Robins HS, Pickering L, Gore M, Nicol DL, Larkin J, Swanton C.

J Pathol. 2013 Dec;231(4):424-32. doi: 10.1002/path.4284.

8.

Multidimensional communication in the microenvirons of glioblastoma.

Broekman ML, Maas SLN, Abels ER, Mempel TR, Krichevsky AM, Breakefield XO.

Nat Rev Neurol. 2018 Aug;14(8):482-495. doi: 10.1038/s41582-018-0025-8. Review.

9.

Tumour heterogeneity and resistance to cancer therapies.

Dagogo-Jack I, Shaw AT.

Nat Rev Clin Oncol. 2018 Feb;15(2):81-94. doi: 10.1038/nrclinonc.2017.166. Epub 2017 Nov 8. Review.

PMID:
29115304
10.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
11.

Revisiting CDK Inhibitors for Treatment of Glioblastoma Multiforme.

Lubanska D, Porter L.

Drugs R D. 2017 Jun;17(2):255-263. doi: 10.1007/s40268-017-0180-1. Review.

12.

Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling.

Bashashati A, Ha G, Tone A, Ding J, Prentice LM, Roth A, Rosner J, Shumansky K, Kalloger S, Senz J, Yang W, McConechy M, Melnyk N, Anglesio M, Luk MT, Tse K, Zeng T, Moore R, Zhao Y, Marra MA, Gilks B, Yip S, Huntsman DG, McAlpine JN, Shah SP.

J Pathol. 2013 Sep;231(1):21-34. doi: 10.1002/path.4230.

13.

Combined EGFR and autophagy modulation impairs cell migration and enhances radiosensitivity in human glioblastoma cells.

Palumbo S, Tini P, Toscano M, Allavena G, Angeletti F, Manai F, Miracco C, Comincini S, Pirtoli L.

J Cell Physiol. 2014 Nov;229(11):1863-73. doi: 10.1002/jcp.24640.

PMID:
24691646
14.

MGMT methylation status: the advent of stratified therapy in glioblastoma?

Hau P, Stupp R, Hegi ME.

Dis Markers. 2007;23(1-2):97-104. Review.

15.

EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing.

Francis JM, Zhang CZ, Maire CL, Jung J, Manzo VE, Adalsteinsson VA, Homer H, Haidar S, Blumenstiel B, Pedamallu CS, Ligon AH, Love JC, Meyerson M, Ligon KL.

Cancer Discov. 2014 Aug;4(8):956-71. doi: 10.1158/2159-8290.CD-13-0879. Epub 2014 Jun 3.

16.

Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity.

Meyer M, Reimand J, Lan X, Head R, Zhu X, Kushida M, Bayani J, Pressey JC, Lionel AC, Clarke ID, Cusimano M, Squire JA, Scherer SW, Bernstein M, Woodin MA, Bader GD, Dirks PB.

Proc Natl Acad Sci U S A. 2015 Jan 20;112(3):851-6. doi: 10.1073/pnas.1320611111. Epub 2015 Jan 5.

17.

Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma.

Murat A, Migliavacca E, Gorlia T, Lambiv WL, Shay T, Hamou MF, de Tribolet N, Regli L, Wick W, Kouwenhoven MC, Hainfellner JA, Heppner FL, Dietrich PY, Zimmer Y, Cairncross JG, Janzer RC, Domany E, Delorenzi M, Stupp R, Hegi ME.

J Clin Oncol. 2008 Jun 20;26(18):3015-24. doi: 10.1200/JCO.2007.15.7164.

PMID:
18565887
18.

Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition.

Turajlic S, Furney SJ, Stamp G, Rana S, Ricken G, Oduko Y, Saturno G, Springer C, Hayes A, Gore M, Larkin J, Marais R.

Ann Oncol. 2014 May;25(5):959-67. doi: 10.1093/annonc/mdu049. Epub 2014 Feb 6.

19.

Intra-tumour heterogeneity - going beyond genetics.

Caiado F, Silva-Santos B, Norell H.

FEBS J. 2016 Jun;283(12):2245-58. doi: 10.1111/febs.13705. Epub 2016 Apr 1. Review.

20.

The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.

Banelli B, Carra E, Barbieri F, Würth R, Parodi F, Pattarozzi A, Carosio R, Forlani A, Allemanni G, Marubbi D, Florio T, Daga A, Romani M.

Cell Cycle. 2015;14(21):3418-29. doi: 10.1080/15384101.2015.1090063.

Supplemental Content

Support Center